针对精确的B细胞淋巴瘤向抗IgM抗体-药物合物的有条件激活
Katrin Schoenfeld1, Julia Harwardt1, Jan Habermann1
1Institute for Organic Chemistry and Biochemistry, Technical University of Darmstadt, Darmstadt, Germany.
Frontiers in immunology
|October 16, 2023
概括
这项研究引入了一种新型抗体-药物结合物,针对癌症B细胞上的IgM. 结合物被掩盖以防止毒性,然后由蛋白酶激活以消除恶性B细胞,同时保持免疫系统.
科学领域:
- 免疫学 免疫学 免疫学
- 在瘤学瘤学.
- 药物开发 药物开发
背景情况:
- 癌症B细胞与正常B细胞共享表面抗原,使向治疗复杂化.
- 消除恶性B细胞,同时保持免疫功能是B细胞淋巴瘤治疗的一个重大挑战.
研究的目的:
- 开发一种针对B细胞淋巴瘤根除IgM的新型抗体-药物联合体 (ADC).
- 设计一种蒙面的ADC,可以选择性地向恶性B细胞并诱导亡.
主要方法:
- 一个特定于IgM的ADC被设计成一个带有掩饰表位的IgM常量域.
- 采用蛋白酶介导的揭示方法来恢复ADC的结合和活性.
- 评估了被揭露的ADC在诱导恶性B细胞中亡的疗效.
主要成果:
- 抗体掩盖防止了对溶性和细胞表面IgM的细胞毒性活性.
- 有条件的蛋白质酶介导解密恢复了ADC的结合能力.
- 在恶性B细胞中实现了依赖于标的内化和亡诱导.
结论:
- 开发的面具抗IgMADC为向的B细胞淋巴瘤根除提供了一个有前途的战略.
- 这种方法有助于选择性消除恶性B细胞,保持免疫功能.
- 这种可适应的平台具有治疗非霍奇金淋巴瘤的潜力.
相关概念视频
B Cell Activation and Differentiation
1.8K
The adaptive immune response, a sophisticated defense mechanism, relies on the activation and differentiation of B lymphocytes, or B cells. These processes enable our bodies to mount a tailored response against specific pathogens such as bacteria, free virus particles, toxins, and parasites.
When naive B cells encounter a specific antigen that can bind to the B cell receptor (BCR) on their surface, they undergo sensitization to respond to the antigen's presence. Sensitization begins with...
When naive B cells encounter a specific antigen that can bind to the B cell receptor (BCR) on their surface, they undergo sensitization to respond to the antigen's presence. Sensitization begins with...
1.8K
Targeted Cancer Therapies
7.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.7K
Hybridoma Technology
14.8K
Hybridoma technology is used for the large-scale production of monoclonal antibodies. Monoclonal antibodies bind to only a single antigenic determinant or epitope. Such antibodies are used in research, diagnostics, and disease therapy. The hybridoma technology established in 1975 by Georges Köhler and Cesar Milstein was awarded the Nobel Prize in Medicine in 1984 for revolutionizing research and therapy.
Hybridoma Selection
Commonly used fusion techniques — electroporation,...
Hybridoma Selection
Commonly used fusion techniques — electroporation,...
14.8K


